Insulin 320
Alternative Names: I320Latest Information Update: 28 Jul 2018
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Germany (PO)
- 11 Sep 2017 Adverse events and pharmacodynamics data from a preclinical trial presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
- 01 Dec 2015 Novo Nordisk completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in Germany (NCT02479022)